We determined the activities of tyrosine aminotransferase (TAT, EC 2.6.1.5), p-hydroxyphenylpyruvate oxidase (p-HPPA oxidase, EC 1.14.2.2) and fumarylacetoacetate fumarylhydrolase (FAH, EC 3.7.12) in cytosol of the liver and kidney tissues obtained at autopsy from a case of hereditary tyrosinemia type I. Values were compared with those from a control group of autopsied tissues from three adults and six children, who had died of other causes. In tyrosinemia, these three hepatic enzyme activities were all decreased: TAT showed approximately 35%, p-HPPA oxidase 11%, and FAH 6090 of the corresponding control values. On the other hand, kidney enzymes in tyrosinemia revealed that FAH was most significantly decreased to approximately 14% of the control activity. K, values for substratedetermined for p-HPPA oxidase and FAH-were not different between the patient and controls, suggesting no altered properties of these enzymes. We conclude that in the present case of hereditary tyrosinemia type I, the activities of p-HPPA oxidase in liver and FAH in kidney were most strikingly affected. This fact may in part explain the deteriorated metabolism of tyrosine observed in this patient. Abbreviations FAH, fumarylacetoacetate fumarylhydrolase p-HPPA, p-hydroxyphenyl-pyruvate TAT, tyrosine aminotransferase
Hereditary tyrosinemia type I, acute form, is an autosomal recessive disorder characterized by failure to thrive, hepatic dysfunction, hypoglycemia, and renal tubular dysfunction. The plasma levels of tyrosine and methionine are markedly elevated and there is increased urinary excretion of tyrosyl compounds (tyrosine, p-HPPA, p-hydroxyphenyllactate, andp-hydroxyphenylacetate). The excessive excretion of phenolic acids has led some investigators (12, 21) to suggest that the enzyme, p-HPPA oxidase, is involved in the pathogenesis of this disorder. In fact, several authors (15, 23) confirmed that the p-HPPA oxidase activity was markedly reduced in the liver of patients; this was once considered to be a primary defect, but still is controversial (2, 8) .
There is now strong speculation that the defect in fumarylacetoacetate degradation may be a leading cause of tyrosinemia type I (1, 1 1, 14, 17) . But it is not yet known whether this defect is the primary cause of this disease. To elucidate whether or not the disease is an inborn error with two enzyme defects, it is necessary to examine not only FAH but also p-HPPA oxidase simultaneously in the patient's liver. In addition, studying these enzyme activities in both the kidney and the liver may shed light on the role of the kidneys in the altered tyrosine metabolism in this disorder.
CASE REPORT
The patient, a male infant, weighing 1700 g was born at 31 wk gestation to a 23-yr-old mother who had mild hyperthyroidism. There was no consanguinity between the parents, and a normal female had been born 14 mo previously. The patient was admitted at 1 d of age with severe jaundice and petechiae over the entire body. The serum concentration of bilirubin rose to 24.0 mg/dl with 11.5 mg/dl direct. The hepatitis B surface antigen test was negative. The SGOT was 444 IU, the SGPT was 270 IU, the alkaline phosphatase 32.8 IU. The serum concentration of calcium was 7.9 mg/dl, blood urea nitrogen 14.4 mgldl, and glucose 41 mg/dl. Titers for rubella, herpes, and cytomegalovirus were not increased. At 1, 2, and 6 d of age he was treated with exchange transfusion. Serum bilirubin had decreased only transiently in response to exchange transfusion, and subsequently increased up to 38.9125.9 mg/dl at d 18 (Fig. 1) . He had intermittent apnea. Carcinoembryonic antigen was 2.2 nglml. Alpha-fetoprotein was above 320 ng/ml. At 17 d of age, his serum tyrosine was found to be extremely high, 13.1 mgldl, and the concentration of methionine was 3.1 mg/dl. At this time, urinary tyrosine metabolites (p-HPPA, p-hydroxyphenyllactate, and p-hydroxyphenylacetate), glycine, threonine, tyrosine, and serine were markedly increased (Table 1) . Treatment was begun with vitamin C (100 mgld) and a low phenylalanine (13 mg. kg-'. d-') low tyrosine (13 mg. kg-' .d-') formula, but he showed no clinical improvement. The diet produced a remarkable fall in serum tyrosine, accompanied by a rise in methionine (Fig. 1) . At 27 d of age, the patient developed acute dyspnea, rapidly became comatose, and died. An autopsy revealed extensive hepatic fibrosis and bile duct proliferation surrounding the nodules. There was no remarkable change in pancreatic islets. The renal tubuli were moderately dilated.
MATERIALS AND METHODS
Amino acids in serum were determined with high performance liquid chromatography (Shimazu-LC-3A). Organic acids in urine were identified and quantitated by gas chromatography-mass spectrometry-computer techniques through the courtesy of Dr. I. Matsumoto (19) . Liver and kidney specimens were obtained from the patient within 4 h after death, and stored at -80°C until used. Control specimens were obtained from three adults and five children at autopsy and stored as described above. Except for two cases (control B and H in Table 2 ), all control patients showed moderate to severe liver dysfunction ( acids at diagnosis, summarized in Table 1 , were p-HPPA, phydroxyphenyllactate, p-hydroxyphenyacetate, glycine, threoFor TAT assay, frozen tissues were homogenized in 9 vol of nine, tyrosine, and serine. 0.14 M KC1 containing 1 mM EDTA and cytosol was obtained
Enzyme activities in cytosol of liver and kidney (Table 2) . by centrifuging at 15,000 g for 30 min. For p-HPPA oxidase Enzyme activities (nmol . min-I . mg protein-') in the patient were assay, tissues were homogenized in 5 vol of 0.1 M potassium compared with those from nine controls in ages from 1-63-yr phosphate buffer, pH 7.3, centrifuged at 15,000 g for 30 min and old. None of the enzyme activities in tissues of the control group the supernatant was used. For FAH assay, tissues were homoge-showed consistent age-related variations. The high TAT activity nized in 9 vol of 0.25 M sucrose and high speed-supernatant was of contiol A was probably due to hepatoma (20). The high obtained by centrifuging at 100,000 g for 60 min. All procedures activity of liver FAH, 65.3, in control E was derived from were camed out at 0-4°C. unknown reasons. In the patient, TAT and FAH in liver were TAT was determined according to the method of Granner et both decreased to approximately 40-60% of the median value al. (10) . p-HPPA oxidase was measured by modifying the isotopic of control tissues. TAT in kidney was in the range of control method of Fellman et al. (6) Range (6.7-30.5) (1 6 1.7) (14.6-64.7) (12.9-16.2) dubious that the defect of tyrosine metabolism was solely in the
step of p-HPPA oxidase, although we confirmed the decreased Km? 2.9 7.5 1.0 + 0.lt 0.7 hepatic p-HPPA oxidase in this case. Range (1.5, 4.3) ...
(0.9-1.1) (0. 6, 0.8) Gaul1 et al. (8) found decreased activities of methionine ad- enosyltransferase and cystathionine P-synthase, as well as p- Vmax' Range (0.9, 1.9) ... (12.0-16.3) (1.7, 1.9) HPPA oxidase, in the liver of tyrosinemia type I and concluded that these enzyme deficiencies were probably secondary mani-* Abbreviations: see "Abbreviations."
festations of an unknown metabolic defect. Previously, we also t PM.
reported deficiencies of both p-HPPA oxidase and methionine
adenosyltransferase in another case of hereditary tyrosinemia "umbers in parentheses represent number of separate assays when type I (7). succinylacetone, possible metabolic products of fumarylacetoacetate, in the urine from three patients with hereditary tyrosinemia type I and postulated that a defect of FAH is responsible for these abnormal metabolites. But the presence of these comaccounted for less than 15% of the control values. When the p-pounds were not reconfirmed by Chalmers and Lawson (3), HPPA oxidase activities were determined by deleting the reduced suggesting that there are heterogenous causes in the pathogenesis form of 2,6-dichloroindophenol from the standard assay, the of hereditary tyrosinemia type I. Nevertheless, several investigaactivities in both tissues were comparably decreased between the tors have identified the FAH deficiency in liver from patients patient and controls (liver, 64% vs 63-8 1 % and kidney, 58% vs with this disease (1, 1 1, 14) .
48-68%). The kinetic characteristics of the p-HPPA oxidase and
In this study, we demonstrated that p-HPPA oxidase in liver FAH were determined using Lineweaver Burke plots. Data are and FAH in kidney were strikingly decreased to the level of onesummarized in Table 3 . The K, of p-HPPA oxidase for p-HPPA tenth of control values. TAT and FAH in liver, and p-HPPA was not different from that of corresponding controls either in oxidase in kidney remained approximately 40% of the control liver or kidney. FAH in liver and kidney of the patient also activities. By interpreting these results, we speculate that a specific showed no difference from control in terms of K, for fumar-enzyme defect may reside at two different steps in separate ylacetoacetate. As expected from the specific activities in Table organs : p-HPPA oxidase in liver and FAH in kidney. In other 2, V,,, alone is different between the patient and control groups. words, it is possible that enzyme defects were multiple and each -f Soluble fraction only.
In conclusion, we describe a case of tyrosinemia type I with rapid fatal course due to hepatic dysfunction. Postmortem study disclosed that activities of p-HPPA oxidase in liver and FAH in kidney were most markedly affected. Though the primary defect is yet unknown, we speculate that the deficient activity of FAH in kidney may play a significant role in the pathogenesis of this disorder. REFERENCES relatively mild loss of enzyme activity. Another interesting aspect in our case is that two sequential enzymes, p-HPPA oxidase and FAH, are involved. Similar findings were described for hereditary orotic acidemia (1 3); however, we are still not sure whether these two enzyme defects account for all of the altered metabolism in our patient. It has been well known that the major enzymes, TAT, p-HPPA oxidase, and homogentisate oxidase, involved in tyrosine degradation to fumarate and acetate, are present mainly in liver and kidney. In this study, we first demonstrated that FAH is abundantly present in contiol kidney tissue as well as in liver (Table  2 ). In terms of the subcellular distribution, these enzymes are mostly in cytosol (5, 6, 14, 24) . Although TAT is known to be distributed both in cytosol and mitochondria, we measured only cytosolic TAT in our case. The significance of FAH deficiency in kidney remains to be elucidated in tyrosinemia. One may argue that the deficient FAH activity in kidney tissues of our patient resulted from renal dysfunction, but no definite signs of renal failure were noted throughout his disease (blood urea nitrogen, 10.8-14.4 mg/dl). As shown in Table 2 , controls D and I, who suffered from severe renal dvsfunction with blood urea
